| CTVA |
Report |
Operating EPS |
BEAT |
pred ~$2.49 vs. cons $2.43 |
MEDIUM |
| CTVA |
Report |
Operating EBITDA |
BEAT |
pred ~$2.31B vs. cons $2.27B |
MEDIUM |
| CTVA |
Report |
Net sales |
BEAT |
pred ~$6.73B vs. cons $6.63B |
MEDIUM |
| CTVA |
Guide |
FY26 operating EBITDA guidance |
BETTER |
guide ~$4.25B midpoint vs. cons $4.20B midpoint (FY26) |
MEDIUM |
| CTVA |
Guide |
FY26 operating EPS guidance |
BETTER |
guide ~$3.80 midpoint vs. cons $3.74 midpoint (FY26) |
MEDIUM |
| CTVA |
Guide |
Separation net dis-synergies |
BETTER |
guide ~$75M vs. cons $90M (FY26) |
MEDIUM |
| CTVA |
Return |
Day-1 residual (stock − beta × S&P 500) |
+4.5% |
— |
MEDIUM |
| CTVA |
Return |
5-day cumulative residual |
+6.5% (FOLLOW-THROUGH) |
The ~$0.06 FY26 EPS midpoint increase versus ~$3.74 consensus and ~$0.05B EBITDA midpoint increase versus ~$4.20B consensus support upward out-period revisions; a lower ~$75M separation-dis-synergy outlook versus ~$90M expected adds valuation support. |
MEDIUM |